A comprehensive, multidisciplinary approach to medical care; early treatment of pulmonary disease; and aggressive management of malnutrition have translated into longer lives for persons with cystic fibrosis (1) (2) (3) . Life expectancy depends on a patient's characteristics as well as his or her access to medical care and medications, which may vary both within and among countries (4, 5) . Comparisons of national cystic fibrosis registry data have led to important discoveries in cystic fibrosis disease progression and increased our understanding of epidemiologic trends in cystic fibrosis mortality and clinical care (6 -12) . Recently, Goss and colleagues (7) showed that among persons aged 6 to 25 years with cystic fibrosis, pulmonary function was greater among patients in the United States than those in the United Kingdom, which was associated with differential prescribing of inhaled mucolytic therapies between the 2 countries.
In 2011, the median age of survival for patients with cystic fibrosis in the U.S. Cystic Fibrosis Foundation Patient Registry (CFFPR) annual data report was 36.8 years, whereas it was 48.5 years in the Canadian Cystic Fibrosis Registry (CCFR) report (13, 14) . Directly comparing estimates of median age of survival between national registry reports is problematic because of the inherent differences in methodologies used, data processing techniques, and ascertainment bias (15, 16) . We recently showed that survival estimates may be over-or underestimated depending on how data are captured and processed, as well as the proportion of missing data (15) . Using a standardized approach to data processing and survival calculations would provide greater confidence in international comparisons and in the identification of factors that may contribute to the observed differences.
The objectives of this study were to determine whether using a standardized approach to data processing and survival calculations would confirm the observed difference between Canada and the United States and, if a survival gap persisted, to explore potential contributing factors. We hypothesized that differences in survival between the countries might be ex-plained by variations in clinical characteristics of the patient populations, differential rates of transplantation, and variations between the health care systems.
METHODS
This population-based cohort study used prospectively collected data from 42 Canadian and 110 U.S. cystic fibrosis care centers from 1990 through 2013. Each center that submits data to the registry obtains patient consent for the data to be collected. This study was approved by the Research Ethics Board of St. Michael's Hospital, Toronto, Ontario, and the Institutional Review Board of Seattle Children's Hospital, Seattle, Washington.
A detailed description of both registries, as well as information on how patients are accrued and monitored within each registry, is outlined in the Supplement (available at Annals.org). The CCFR and CFFPR contain detailed demographic and clinical information on patients with a confirmed diagnosis of cystic fibrosis (17) receiving clinical care at accredited cystic fibrosis centers across Canada and the United States. The registries collect data on age, sex, age at diagnosis, race, symptoms at presentation, whether the patient was diagnosed through newborn screening, date of transplantation, and date and cause of death, as well as anthropometric measurements, lung function, bacteriology, cystic fibrosis-related complications, and pancreatic status.
The research team evaluated each variable in the Canadian and U.S. registries and made comparisons regarding data definitions and how data are collected to establish a unified approach to each variable. Because the CCFR records the first stable clinical measurement per person per year, we selected the first stable measurement of the year for each patient in the CFFPR to mirror data collection methods. A stable measurement was defined as one that was taken from a routine outpatient clinic visit when the patient was not being treated for a pulmonary exacerbation. Missing date of diagnosis was imputed by using date of birth plus 30 days, whereas age at diagnosis was categorized as less than 2 or 2 or more years of age (18) . Genotype was classified as homozygous delta F508, heterozygous delta F508, other, or missing. Race was categorized as white, other, or missing. The FEV 1 was expressed as a percentage of the predicted values for healthy age-and sex-matched controls by using Global Lung Function Initiative reference equations (19) . Body mass index (BMI) percentile was calculated for children between 2 and 19 years of age by using the Centers for Disease Control and Prevention growth charts (20) . Children were then classified as underweight (BMI percentile, ≤12%), adequate weight (BMI percentile, 13% to 84%), or overweight (BMI percentile, ≥85%) (21) . For persons aged 19 years and older, BMI was categorized according to World Health Organization guidelines (22) as underweight (<18.5 kg/m 2 ), adequate weight (18.5 to 24.9 kg/m 2 ), or overweight (≥25.0 kg/m 2 ). On the basis of the literature, respiratory bacteria may have a differential effect on survival. We categorized patients whose respiratory tract specimens grew several organisms in a given year according to the organism that carried the worst prognosis in terms of survival. This categorization allowed us to create mutually exclusive groups to avoid combining less virulent organisms with ones associated with a worse prognosis. On the basis of this hierarchical classification, patients with several types of bacteria cultured in a given year were categorized as follows: Burkholderia cepacia complex took precedence over any other type of infection, methicillin-resistant Staphylococcus aureus took precedence over Pseudomonas aeruginosa, and P aeruginosa took precedence over all remaining organisms. Cystic fibrosis-related diabetes (CFRD) was defined by the clinic according to published consensus guidelines (23) . Pancreatic status was determined by patients' use of pancreatic enzyme replacement therapy; it was used as a surrogate for disease severity in the multivariable analysis, because CFTR (cystic fibrosis transmembrane conductance regulator) genotype and pancreatic status are highly correlated (24) , and few patients had missing data for pancreatic enzyme replacement therapy. Previous literature suggests that most patients reported as lost to follow-up at some point during follow-up will return to the cystic fibrosis center within 2 years of nonattendance (5). Thus, patients were considered lost to follow-up if they had no death date recorded and their last reporting year was more than 2 years from the end of the study.
The single-payer universal health insurance program in Canada provides comprehensive medical care to all Canadian citizens, whereas the United States uses a multipayer approach to health care. Patients in the United States were grouped into mutually exclusive categories according to their health insurance coverage as follows: continuous Medicaid or Medicare (receiving Medicare and/or Medicaid in all 5 years), intermittent Medicaid or Medicare (receiving Medicaid and/or Medicare in at least 1 but not all 5 years), other (any other insurance besides Medicaid or Medicare-predominantly employer-provided private insurance), and none or unknown (no or unknown insurance in all 5 years).
Statistical Analyses
Demographic and clinical variables were summarized by country, with categorical variables expressed as frequency and proportion and continuous variables summarized as median and range. Differences between countries were compared by using the MannWhitney U test for continuous variables and the chisquare test for categorical variables. P values are heavily influenced by sample size; thus, the large sample sizes herein will render very small differences statistically significant. As such, the standardized difference (SD) was used to determine statistical significance. An SD greater than 10 was used to determine statistically significant differences between the countries (25) .
We used period survival analysis to calculate median age of survival estimates over time. Median age of ORIGINAL RESEARCH Survival in Cystic Fibrosis Between Canada and the United States survival for each year was calculated for each 5-year window beginning with the period 1986 to 1990 and ending with 2009 to 2013. Differences in median age of survival between the 2 countries over time were evaluated from 1990 to 2013 by using segmented regression analysis to determine whether significant change points emerged when the differences in median age of survival diverged (26) .
We further explored differences in survival by adjusting for patient and clinical characteristics with a multivariable Cox proportional hazards model that used data from the most recent 5 years (2009 to 2013), which reflected a contemporary cohort of patients with cystic fibrosis. The multivariable Cox proportional hazards analysis was first conducted on data from all patients, including those who received transplants, and adjusted for time-independent characteristics (sex, race, age at diagnosis, and pancreatic status) and transplant status. Subsequently, we conducted additional multivariable analyses that included time-varying clinical characteristics known to be prognostic for patient survival, such as FEV 1 , BMI, CFRD, and microbiology. We excluded patients younger than 6 years because lung function measurements are not reliably measured until the age of 6 years. Because clinical outcomes after transplantation, particularly FEV 1 , do not represent cystic fibrosis lung disease, this analysis censored patients at the time of transplantation. Country, sex, age at diagnosis, race, genotype, pancreatic status, and insurance status were modeled as time-independent covariates. Missing lung function and BMI measurements were imputed by using multiple imputation (27) (see the Supplement for additional details on survival calculations and imputation methodology).
Patients with milder clinical phenotypes have longer survival; therefore, differences in the proportions of patients with milder cystic fibrosis disease in the 2 countries would bias the survival estimates. To address this potential ascertainment bias, we conducted several subgroup analyses. The multivariable Cox proportional hazards models were repeated, limiting the sample to patients with a severe clinical phenotype as defined by pancreatic status (that is, patients with pancreatic insufficiency), those with homozygous delta F508 disease, and those who received their diagnosis before the age of 2 years (17, 28) . To address the differences in health care systems between the 2 countries, we further classified the U.S. patients by insurance status and compared the risk for death in these subgroups with that of Canada, which has universal health care, as a whole. The insurance status classification was used in previous studies, because Medicaid and Medicare have been associated with worse outcomes in cystic fibrosis (29, 30) . Because the hierarchical approach to microbiology used in our study has not been used commonly in registry studies, we conducted a sensitivity analysis in which we classified pertinent individuals as having co-infections with several bacteria.
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RESULTS

Longitudinal Trends in Survival Over Time (1990 to 2013)
Between 1990 and 2013, the U.S. and Canadian cystic fibrosis registries followed 45 448 and 5941 patients, respectively, with 9654 (21.2%) and 1288 (21.7%) deaths, respectively. Demographic and clinical characteristics of these patients are listed in Supplement Table 1 (available at Annals.org). Median age of survival in both countries increased over the study period ( Figure 1, top) . However, the rate of improvement in median age of survival over time between the 2 countries diverged in 1995 and 2005 (Davies test; P < 0.001) (Figure 1, bottom) , most notably in 2005, when the improvements in the Canadian population were greater. The rate of change in survival between males and females differed by country (P < 0.001). Survival in Canadian males increased at a significantly faster rate than in U.S. males (P < 0.001) from 2005 onward, whereas no statistically significant difference was seen in survival improvement over time in Canadian versus U.S. females (P = 0.19). Changes in the median age at death over time and the difference in median age at death between the 2 countries are summarized in the Supplement Figures 1 and 2 (available at Annals.org). Survival in Cystic Fibrosis Between Canada and the United States ORIGINAL RESEARCH NA = not available; SD = standardized difference. * Percentages may not sum to 100 due to rounding. All values are summarized on the basis of the last recorded measurement in the time period. † Unless otherwise indicated. ‡ Differences between countries were compared by using the Mann-Whitney U test for continuous variables and the chi-square test for categorical variables. P values are heavily influenced by sample size; thus, these large sample sizes would render very small differences statistically significant. As such, the SD was used to determine statistical significance. § The mean difference as a percentage of the average SDs. A value >10 was generally used to determine the variables that remained sufficiently different between the 2 countries. ͉͉ Only the patient's first transplantation of any type was considered. ¶ Defined as patients who are alive but whose last available year of data was >2 y before the cohort end year. That is, a patient would be considered lost to follow-up if his or her last available reporting year was 2011 or earlier. 
years]).
The median age at death was 26.9 years in the United States and 31.9 years in Canada (SD, 29.5). The risk for death was consistently lower in Canada than the United States in several population subgroups (Figure 2) . To account for the difference between the 2 countries in the number of patients lost to follow-up after transplantation, we recalculated median survival age, censoring patients on the date of transplant, which effectively excluded posttransplant survival time as well as deaths after transplantation in both countries. This analysis caused the survival gap between Canada and the United States to widen further (57.1 vs. 44.0 years, respectively).
Details regarding the creation of the study cohort used for the multivariable analysis are presented in Figure 3 , and a summary of the demographic and clinical characteristics of the included patients is provided in Supplement Table 3 , available at Annals.org). To address potential ascertainment bias, the analyses were limited to severe patient phenotypes. Canadian patients with cystic fibrosis consistently had a statistically significantly lower risk for death in all subgroups (Supplement Tables 4 to 6, available at Annals.org). Further, results were unchanged regardless of the method used to classify patients into microbiologic categories (Supplement Table 7 , available at Annals.org).
DISCUSSION
Our study confirms a significant survival gap between Canada and the United States in persons living with cystic fibrosis. In the most recent period (2009 to 2013), a 10-year survival advantage was identified for patients living in Canada, which does not seem to be attributed to methodology or data processing techniques. The risk for death was consistently lower in Canada after accounting for several patient demographic and clinical factors and persisted in patients with severe clinical phenotypes. The systematic approach used to compare data from these 2 countries demonstrates that national disease registries can be meaningfully compared and may elucidate factors associated with differences in survival. Although we cannot draw definitive causal inferences from these analyses, the observed differences raise the question of whether a disparity exists in access to therapeutic approaches or health care delivery such that hypotheses may be generated for further investigation.
Although our study was not designed specifically to evaluate the effect of transplantation on survival, few therapeutic interventions have the ability to affect survival in a short period, and several of our findings support the hypothesis that transplantation may be contributing to the observed survival gap. First, although Canada and the United States had similar proportions of patients with cystic fibrosis who had severe lung disease based on FEV 1 during the study period, more Canadian than U.S. patients received a transplant. Second, a greater proportion of deaths in the United States 
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The hazard ratio and 95% CI for each variable are displayed. The dashed line is the null line, indicating no difference between countries.
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than Canada occurred in patients who had not received a transplant. Third, when we censored patients at transplantation, the median age of survival increased from 10 to 13 years, suggesting that transplantation contributes to the survival gap. Finally, we observed a significant widening of the survival gap between the countries since 2005; in May of that year, prioritization of U.S. patients with cystic fibrosis for lung transplantation changed markedly with implementation of the lung allocation score (LAS), which is not used in Canada (31) . Existing literature further supports the possible role that transplantation plays in the Canada-U.S. survival gap. For instance, median survival is longer in Canadian patients with cystic fibrosis after lung transplantation compared with data from published studies in U.S. patients with cystic fibrosis who received transplants (32, 33) . Ramos and colleagues (34) showed that 35% of potentially eligible U.S. patients with cystic fibrosis were not referred for transplantation despite meeting selected criteria for lung transplant evaluation. Although the LAS used in the United States has been associated with shorter wait times and increased transplant survival (35) , and the number of patients with cystic fibrosis listed for lung transplantation has increased since its implementation, the proportion who have received a transplant has decreased (36) . In addition, Merlo and colleagues (35) showed that patients with cystic fibrosis who received transplants since the LAS was implemented had a higher risk for death than those who received transplants in the pre-LAS period. These studies suggest that differential access to lung transplantation and survival afterward between Canada and the United States may contribute to the survival gap, although this hypothesis requires further study.
Although transplantation may play a role, other factors likely are contributing to the survival gap, such as the substantial difference in health care delivery between Canada and the United States. In Canada, universal health care provides all persons with the opportunity to access medical services across the country; in the United States, differences in health insurance coverage affect access to medical care and costs of care and are related to socioeconomic status (SES) (30, 33) . Indeed, we observed that health insurance status in the United States had a differential effect on the risk for death for persons with cystic fibrosis living in the United States compared with those in Canada. Of interest, no statistically significant difference in risk for death was seen between Canadian patients and U.S. patients with The percentage of excluded deaths for each country was calculated by dividing the total number of excluded deaths by the total number of initial deaths in each country. other insurance (primarily private coverage). We could not draw firm conclusions on the effect of SES on the survival gap, because the Canadian registry does not capture SES data. Although all Canadians have access to health care regardless of SES, this does not imply that SES has no effect on survival in Canada, where hidden financial factors, such as costs associated with time off from work, driving long distances to be seen at a cystic fibrosis clinic, or having to relocate to a cystic fibrosis transplant center, may limit patients' ability to seek medical attention. The fact that the risk for death in the United States varied depending on the type of health insurance coverage raises the possibility that differences in the health care systems may explain part of the survival gap documented; however, further study is needed to formally evaluate this question. Previous comparisons between Canada and the United States in the 1980s suggested that implementation of aggressive nutritional support in the early 1970s in Toronto led to increased survival there compared with Boston (6). As a result, a high-fat diet was adopted worldwide for persons with cystic fibrosis. Those born in Canada in the 1970s would have been exposed to aggressive nutritional supplementation from birth, and the effect of this early support would have reduced their risk for death in their later teenage and early adult years. As such, one would expect that U.S. survival would catch up to Canada's, because cystic fibrosis centers in the United States also implemented the highcalorie diet, albeit 5 to 10 years later.
The strengths of our study include the large sample size, the longitudinal data within both cystic fibrosis registries, the consistency of our results across several subgroups, and our unified approach to the analysis. Both registries have a high participation rate, and cystic fibrosis clinics receive financial incentives for data submission, resulting in a comprehensive national picture of the cystic fibrosis population. However, missing vital statistics may result in biased survival estimates, particularly if one country had a disproportionate number of missing events compared with the other (15) . Previous literature suggested that death dates are missing in the CFFPR, particularly for patients older than 45 years, when compared with national vital statistics (37), whereas the number of deaths in the CCFR is similar to that reflected in Canadian vital statistics (5) . If the U.S. data were preferentially missing deaths, this would result in an overestimation of true U.S. cystic fibrosis survival. Our data also show that more U.S. than Canadian patients were lost to follow-up, which would have the opposite effect on survival estimates (typically, a greater number of patients lost to follow-up results in an underestimation of median survival) (15) . Also worth noting is that more U.S. than Canadian patients lost to follow-up had characteristics associated with a worse prognosis, such as female sex, nonwhite race, pancreatic insufficiency, and CFRD (Supplement Table 8 ). By preferentially excluding U.S. patients with a worse prognosis from the survival analysis, the survival gap may actually be wider than reported in our study. Differences between the registries regarding inclusion of patients with a mild clinical phenotype might result in a survival gap, simply because one country captures patients with mild disease and the other does not. The fact that our findings were consistent across several subgroups, including those with a severe clinical phenotype, suggests that longer survival in Canada than the United States is not the result of following patients with milder disease in the Canadian cohort. Differences in medication use may play a role in the survival gap; between 2011 and 2013, medication use was greater in the United States, but we could not examine medication use for the full study period because of the lack of medication data before 2011 in Canada. Although environmental factors, such as air pollution or climate, may affect lung health in cystic fibrosis, these data were not equally available within the registries (air pollution data have been linked only to the CFFPR). Newborn screening programs have been in place longer in the United States than Canada; however, this likely has no significant effect on the current survival estimates, because relatively few pediatric deaths occur in either country. Furthermore, having more extensive newborn 
screening programs in the United States would bias the results toward the null, because these patients presumably would be healthier. Regional or center-specific death rates between the countries were not examined because of the relatively few deaths within any given center, which would produce unreliable survival estimates.
In conclusion, we show a difference in survival between Canada and the United States, even after adjusting for patient characteristics and clinical factors known to be associated with survival, with the exception of private-insurance status among U.S. patients. The survival differences appear to diverge at 2 distinct time points, most notably in 2005, when the gap between the 2 countries widened. Differential access to transplantation related to the referral or donor lung allocation process; variable posttransplant survival; and differences in health care systems, including access to insurance, may, in part, explain the Canadian survival advantage. Further studies are necessary to specifically test these hypotheses.
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